Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...

Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...

Shares of Omeros touched a 52-week high, a day after the company said it could resubmit its biologics license application for narsoplimab to the Food and Drug Administration. In Thursday afternoon ...

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

They will also evaluate the impact of ECP on the development of transplant-associated thrombotic microangiopathy (TA-TMA). "Mallinckrodt is thrilled to recognize Dr. Andrea Varkonyi with this year's ...

As described in previous updates, we have been working closely with FDA regarding the anticipated resubmission of our Biologics License Application, or BLA for narsoplimab in hematopoietic stem cell ...

Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has ...

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

A new paper shows how partnering with the community can lead to more inclusive health care, especially for individuals with autism and other neurodevelopmental disabilities.

Without a permanent implant, there’s a reduced risk of chronic inflammation, thrombotic complications, and need for prolonged antiplatelet therapy. Additionally, a metal-free strategy aligns well with ...